col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


50 Results       Page 1

 [1] 
Springer Science and Business Media LLC: Molecular Psychiatry
  original article Date Title Authors   All Authors
1 [GO] 2024―Jan―18 Risk for diagnosis or treatment of mood or anxiety disorders in adults after SARS-CoV-2 infection, 2020-2022 Christina X. Wang, Rhea Kohli, Veronica R. Olaker, Pauline Terebuh, Rong Xu, David C. Kaelber, Pamela B. Davis
2 [GO] 2023―Dec―19 Composite healthy lifestyle, socioeconomic deprivation, and mental well-being during the COVID-19 pandemic: a prospective analysis Gang Hu, Huibo Qin, Binbin Su, Yanping Bao, Zhengting Liang, Yunhe Wang
3 [GO] 2023―Aug―03 The risk of hospitalization for psychotic disorders following hospitalization for COVID-19: a French nationwide longitudinal study Baptiste Pignon, Valentina Decio, Philippe Pirard, Olivier Bouaziz, Emmanuelle Corruble, Pierre A. Geoffroy, et al. (+8)
4 [GO] 2023―Jul―25 Epidemiology, clinical presentation, pathophysiology, and management of long COVID: an update Sizhen Su, Yimiao Zhao, Na Zeng, Xiaoxing Liu, Yongbo Zheng, Jie Sun, et al. (+14)
5 [GO] 2023―Jul―19 Depression and anxiety before and at the beginning of the COVID-19 pandemic and incident persistent symptoms: a prospective population-based cohort study Joane Matta, Olivier Robineau, Emmanuel Wiernik, Fabrice Carrat, Gianluca Severi, Mathilde Touvier, et al. (+10)
6 [GO] 2023―Jul―04 Detrimental effects of COVID-19 in the brain and therapeutic options for long COVID: The role of Epstein-Barr virus and the gut-brain axis Kenji Hashimoto
7 [GO] 2023―Apr―17 The impact of preexisting psychiatric disorders and antidepressant use on COVID-19 related outcomes: a multicenter study Katharina Schultebraucks, Wivine Blekic, Cale Basaraba, Tom Corbeil, Zain Khan, Brandy F. Henry, et al. (+7)
8 [GO] 2023―Mar―03 Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study Bruce J. Kirenga, Levicatus Mugenyi, Marina Sánchez-Rico, Henry Kyobe, Winters Muttamba, Raymond Mugume, et al. (+13)
9 [GO] 2023―Jan―23 The phenotype and prediction of long-term physical, mental and cognitive COVID-19 sequelae 20 months after recovery, a community-based cohort study in China Yimiao Zhao, Le Shi, Zhendong Jiang, Na Zeng, Huan Mei, Yu Lu, et al. (+17)
10 [GO] 2022―Dec―23 When 1 + 1 = 3: the COVID-19 and addiction syndemic Gavin Bart
11 [GO] 2022―Dec―13 Association of COVID-19 with endocarditis in patients with cocaine or opioid use disorders in the US Lindsey Wang, Nora D. Volkow, Nathan A. Berger, Pamela B. Davis, David C. Kaelber, Rong Xu
12 [GO] 2022―Dec―06 Reply to “Predominance of visuoconstructive impairment after mild COVID-19?” by Díez-Cirarda et al. 2022 Jonas J. de Paula, Fabio L. S. Duran, Geraldo Busatto, Debora M. Miranda, Marco A. Romano-Silva
13 [GO] 2022―Nov―01 SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein Eduardo A. Albornoz, Alberto A. Amarilla, Naphak Modhiran, Sandra Parker, Xaria X. Li, Danushka K. Wijesundara, et al. (+27)
14 [GO] 2022―Oct―07 Impact of the COVID-19 pandemic on non-COVID-19 hospital mortality in patients with schizophrenia: a nationwide population-based cohort study Laurent Boyer, Guillaume Fond, Vanessa Pauly, Veronica Orléans, Pascal Auquier, Marco Solmi, et al. (+5)
15 [GO] 2022―Oct―05 Neurogenesis is disrupted in human hippocampal progenitor cells upon exposure to serum samples from hospitalized COVID-19 patients with neurological symptoms Alessandra Borsini, Blair Merrick, Jonathan Edgeworth, Gargi Mandal, Deepak P. Srivastava, Anthony C. Vernon, et al. (+3)
16 [GO] 2022―Oct―05 The relationship of adverse childhood experiences, hair cortisol, C-reactive protein, and polygenic susceptibility with older adults’ psychological distress during the COVID-19 pandemic Katie S. Taylor, Andrew Steptoe, Eleonora Iob
17 [GO] 2022―Oct―05 SARS-CoV-2 promotes microglial synapse elimination in human brain organoids Ana O. Oliveira, Susmita Malwade, Nuno Rufino de Sousa, Sravan K. Goparaju, Jessica Gracias, Funda Orhan, et al. (+6)
18 [GO] 2022―Sep―19 Predominance of visuoconstructive impairment after mild COVID-19? María Díez-Cirarda, Miguel Yus, Jorge Matías-Guiu, Jordi A. Matias-Guiu
19 [GO] 2022―Jun―15 Case-control study of neuropsychiatric symptoms in electronic health records following COVID-19 hospitalization in 2 academic health systems Victor M. Castro, Jonathan Rosand, Joseph T. Giacino, Thomas H. McCoy, Roy H. Perlis
20 [GO] 2022―Jun―14 Selective visuoconstructional impairment following mild COVID-19 with inflammatory and neuroimaging correlation findings Jonas Jardim de Paula, Rachel E. R. P. Paiva, Nathália Gualberto Souza-Silva, Daniela Valadão Rosa, Fabio Luis de Souza Duran, Roney Santos Coimbra, et al. (+20)
21 [GO] 2022―Jun―06 A systematic review and meta-analysis on prevalence of and risk factors associated with depression, anxiety and insomnia in infectious diseases, including COVID-19: a call to action Kai Yuan, Yong-Bo Zheng, Yi-Jie Wang, Yan-Kun Sun, Yi-Miao Gong, Yue-Tong Huang, et al. (+27)
22 [GO] 2022―Jun―06 A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: call for research priority and action Na Zeng, Yi-Miao Zhao, Wei Yan, Chao Li, Qing-Dong Lu, Lin Liu, et al. (+17)
23 [GO] 2022―Apr―22 COVID-19 and severe mental illness in Israel: testing, infection, hospitalization, mortality and vaccination rates in a countrywide study Nehama Goldberger, Tal Bergman-Levy, Ziona Haklai, Rinat Yoffe, Michael Davidson, Ehud Susser, et al. (+3)
24 [GO] 2022―Apr―06 Comments to “Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and Entezari-Maleki Yaeko Hashimoto, Takuji Suzuki, Kenji Hashimoto
25 [GO] 2022―Apr―06 Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists Elnaz Khani, Taher Entezari-Maleki
26 [GO] 2022―Feb―08 The 90 plus: longevity and COVID-19 survival Mayana Zatz, Monize V. R. Silva, Mateus V. de Castro, Michel S. Naslavsky
27 [GO] 2022―Jan―21 Implications of parental stress on worsening of behavioral problems in children with autism during COVID-19 pandemic: “the spillover hypothesis” Adrien A. Eshraghi, Leylane Cavalcante, Emily Furar, Michael Alessandri, Rebecca S. Eshraghi, F. Daniel Armstrong, Rahul Mittal
28 [GO] 2022―Jan―12 In COVID-19, NLRP3 inflammasome genetic variants are associated with critical disease and these effects are partly mediated by the sickness symptom complex: a nomothetic network approach Michael Maes, Walton Luiz Del Tedesco Junior, Marcell Alysson Batisti Lozovoy, Mayara Tiemi Enokida Mori, Tiago Danelli, Elaine Regina Delicato de Almeida, et al. (+4)
29 [GO] 2022―Jan―07 Mechanisms of action of fluvoxamine for COVID-19: a historical review Yaeko Hashimoto, Takuji Suzuki, Kenji Hashimoto
30 [GO] 2021―Dec―07 Disparities in COVID-19 infection, hospitalisation and death in people with schizophrenia, bipolar disorder, and major depressive disorder: a cohort study of the UK Biobank Lamiece Hassan, Niels Peek, Karina Lovell, Andre F. Carvalho, Marco Solmi, Brendon Stubbs, Joseph Firth
31 [GO] 2021―Nov―26 Comorbid medical conditions are a key factor to understand the relationship between psychiatric disorders and COVID-19-related mortality: Results from 49,089 COVID-19 inpatients Nicolas Hoertel, Marina Sánchez-Rico, Juan José Herrera-Morueco, Pedro de la Muela, Erich Gulbins, Johannes Kornhuber, et al. (+4)
32 [GO] 2021―Oct―04 The acid sphingomyelinase/ceramide system in COVID-19 Johannes Kornhuber, Nicolas Hoertel, Erich Gulbins
33 [GO] 2021―Sep―27 A systematic review and meta-analysis on the prevalence of stigma in infectious diseases, including COVID-19: a call to action Kai Yuan, Xiao-Lin Huang, Wei Yan, Yu-Xin Zhang, Yi-Miao Gong, Si-Zhen Su, et al. (+18)
34 [GO] 2021―Aug―12 Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms Nicolas Hoertel, Marina Sánchez-Rico, Céline Cougoule, Erich Gulbins, Johannes Kornhuber, Alexander Carpinteiro, et al. (+6)
35 [GO] 2021―Aug―04 Stress-related emotional and behavioural impact following the first COVID-19 outbreak peak Asaf Benjamin, Yael Kuperman, Noa Eren, Ron Rotkopf, Maya Amitai, Hagai Rossman, et al. (+6)
36 [GO] 2021―Jul―20 Post-traumatic stress symptoms in COVID-19 survivors: a self-report and brain imaging follow-up study Yiheng Tu, Yuqi Zhang, Yu Li, Qing Zhao, Yanzhi Bi, Xuejing Lu, et al. (+4)
37 [GO] 2021―Jul―19 Can antidepressants unlock prescription of rimonabant in the fight against COVID-19? Juliette Salles, Fabienne Briand-Mésange, Stéphanie Trudel, Jérôme Ausseil, Jean-Pierre Salles, Hugues Chap
38 [GO] 2021―Feb―17 Mechanisms for substance use disorders in COVID-19 Zhicheng Lin
39 [GO] 2021―Feb―04 Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study Nicolas Hoertel, Marina Sánchez-Rico, Raphaël Vernet, Nathanaël Beeker, Anne-Sophie Jannot, Antoine Neuraz, et al. (+11)
40 [GO] 2021―Feb―04 Prevalence of posttraumatic stress disorder after infectious disease pandemics in the twenty-first century, including COVID-19: a meta-analysis and systematic review Kai Yuan, Yi-Miao Gong, Lin Liu, Yan-Kun Sun, Shan-Shan Tian, Yi-Jie Wang, et al. (+16)
41 [GO] 2021―Jan―22 The impact of quarantine on mental health status among general population in China during the COVID-19 pandemic Yunhe Wang, Le Shi, Jianyu Que, Qingdong Lu, Lin Liu, Zhengan Lu, et al. (+9)
42 [GO] 2020―Dec―16 Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology Deidiane Elisa Ribeiro, Ágatha Oliveira-Giacomelli, Talita Glaser, Vanessa F. Arnaud-Sampaio, Roberta Andrejew, Luiz Dieckmann, et al. (+4)
43 [GO] 2020―Dec―14 Social media and smartphone app use predicts maintenance of physical activity during Covid-19 enforced isolation in psychiatric outpatients Agnes Norbury, Shelley H. Liu, Juan José Campaña-Montes, Lorena Romero-Medrano, María Luisa Barrigón, Emma Smith, et al. (+3)
44 [GO] 2020―Sep―30 Correction: COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States Quan Qiu Wang, David C. Kaelber, Rong Xu, Nora D. Volkow
45 [GO] 2020―Sep―14 Changes in network centrality of psychopathology symptoms between the COVID-19 outbreak and after peak Yuanyuan Wang, Zhishan Hu, Yi Feng, Amanda Wilson, Runsen Chen
46 [GO] 2020―Sep―14 COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States Quan Qiu Wang, David C. Kaelber, Rong Xu, Nora D. Volkow
47 [GO] 2020―Sep―01 The COVID-19 pandemic and epidemiologic insights from recession-related suicide mortality Tarun Bastiampillai, Stephen Allison, Jeffrey C. L. Looi, Julio Licinio, Ma-Li Wong, Seth W. Perry
48 [GO] 2020―Aug―10 A paradox of social distancing for SARS-CoV-2: loneliness and heightened immunological risk Liron Rozenkrantz, Michael H. Bernstein, Christopher C. Hemond
49 [GO] 2020―Jul―28 Molecular Psychiatry, August 2020: new impact factor, and highlights of recent advances in psychiatry, including an overview of the brain’s response to stress during infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Julio Licinio, Ma-Li Wong
50 [GO] 2020―May―07 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis Charlotte Steenblock, Vladimir Todorov, Waldemar Kanczkowski, Graeme Eisenhofer, Andreas Schedl, Ma-Li Wong, et al. (+5)
 [1] 

50 Results       Page 1


[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.016 sec